3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
95
Recurrence
11
Neoplasms, Plasma Cell
9
Immunoglobulin Light-chain Amyloidosis
6
Neoplasms
5
Smoldering Multiple Myeloma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Waldenstrom Macroglobulinemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmacytoma
2
Neoplasm, Residual
2
Lymphoma
2
Leukemia, Plasma Cell
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Renal Insufficiency
1
Prostatic Neoplasms
1
Plasmablastic Lymphoma
1
Paraproteinemias
1
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
1
Myelodysplastic Syndromes
1
Microsatellite Unstable Colorectal Cancer
1
Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Hypergammaglobulinemia
1
Disease
1
Chromosome 17 deletion
1
Interventions
pomalidomide
2
daratumumab
2
Dexamethasone
2
ixazomib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
cc-486
1
auricularum
1
Radiotherapy
1
Peripheral Blood Stem Cell Transplantation
1
Panobinostat
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Lenalidomide
1
Gemcitabine
1
Drug Combinations
1
Calcium Dobesilate
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Plasmacytoma
×
daratumumab
×
Clear all
NCT01946477
2026-05-22
POM MM 014
Celgene
Phase 2
Completed
186 enrolled
17 charts
NCT04065308
2019-08-22
Dara_DCEP
Seoul National University Hospital
Phase 2
Unknown
33 enrolled